Compounded GLP-1 medications occupy a contested middle ground between brand-name Wegovy and Zepbound on the high end and generic semaglutide (available outside the US through 2031) on the low end. Compounded versions filled the gap during the 2022-2024 semaglutide and tirzepatide shortages and built a $1B+ cash-pay market through telehealth platforms. The FDA declared the semaglutide and tirzepatide shortages resolved in early 2025, then proposed on April 30, 2026 to exclude both drugs plus liraglutide from the 503B bulks list — public comments close June 29, with the final determination expected late Q3 2026.
May 2026 telehealth pricing sits at the floor: Ozari Health launched May 19 at $86/month for compounded semaglutide and $120/month for compounded tirzepatide, joining Sesame ($99/month), Henry Meds ($129-249/month), Wisp ($199/month), and Mochi Health ($129/month introductory). The Hims & Hers pivot to branded GLP-1 distribution (Novo deal March 26) plus the FDA AI-Informed Inspection Pilot announced May 15 signal the regulatory and competitive vise tightening around the compounded segment.
Stories here cover telehealth pricing, FDA regulatory action on 503A and 503B compounding, and the medical and legal implications for the patients currently on compounded products. See #503a-compounding, #telehealth, and #semaglutide for adjacent threads.
Using Nebraska's prescription monitoring database, Joey Mattingly's team found compounded GLP-1s went from zero in 2018 to 86% of all compounded weight-loss prescriptions in 2025, almost all paid in cash. Common additives included vitamin B12 analogs such as cyanocobalamin and levocarnitine, which are marketed to ease side effects but have not been tested for safety with GLP-1s, the university said. Mattingly urged doctors to ask patients directly about compounded use, since it rarely shows up in claims data.
In CDC's Rapid Surveys System, 9.8% of 8,118 adults surveyed in July and August 2025 said they had taken a GLP-1 drug in the past 12 months, according to a report in the November 12 MMWR. Among users, 22.6% said they took a compounded version and 44% said they had changed their use from what was prescribed, most often by skipping doses (28%); 54% of users aged 18 to 39 made changes vs. 30% of those 65 and older, as did 62% of compounded-drug users vs. 36% of others. Among those who made changes, 38% cited cost and 36% availability, and about 12% of all users said they cut back or stopped because of side effects.
FDA's October 14, 2026 enforcement report lists 18 Class II recall entries, classified October 8, for compounded injectables for lack of assurance of sterility. Apothecary Pharma of Cary, North Carolina recalled 22 multi-dose vials of tirzepatide 18 mg/mL and one NAD+ vial distributed nationwide, starting September 24; Carolina Infusion of Ridgeland, South Carolina recalled patient-specific syringes of tirzepatide, tirzepatide and semaglutide blended with cyanocobalamin (vitamin B12), semaglutide, sermorelin, and erectile-dysfunction mixes, citing processing equipment and, for some products, a formulation using bacteriostatic water. Fox station coverage on October 21 noted that no illnesses or injuries were reported and that FDA had sent Apothecary Pharma a warning letter in December 2025 over sterile manufacturing practices, without linking it to the recall.
FDA inspection reports obtained by Bloomberg through a Freedom of Information Act request describe black mold on equipment, "gross contamination" on floors, and "significant insect activity" in ceilings at Chengdu Shengnuo Biopharm in southwest China, inspected in August, where staff moved documents to lockers and poured product samples into sinks. A September inspection found that Nanjing Chengong Pharmaceutical had bought active ingredients from other factories and applied its own seal without reviewing their test data. FDA's Import Alert 66-40 lists Chengdu Shengnuo as of September 19, 2026 and Nanjing Chengong as of October 1, so their products can be detained at the U.S. border; the companies made semaglutide and tirzepatide ingredients used in compounded drugs.
A 2026 chemistry study documented that when tirzepatide is compounded with vitamin B12 (a common differentiating additive used by compounding pharmacies to distinguish compounded products from the FDA-approved Mounjaro and Zepbound Eli Lilly formulations), the two substances can chemically bond and form a new molecule not present in the FDA-approved drug product. The finding adds to the accumulating pharmacovigilance case against compounded GLP-1 formulations, which are marketed as bioequivalent to the branded products but frequently contain non-FDA-approved additives whose long-term safety, immunogenicity, and pharmacokinetic profiles have not been characterized in registered clinical trials. Compounding-pharmacy additives often introduce impurities and reaction products that differ from the branded label chemistry. The chemistry-specific finding on tirzepatide + B12 bonding is the type of documented novel-molecule outcome that FDA safety scientists cited in the underlying rationale for the April 30, 2026 proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List. FDA Adverse Event Reporting System (FAERS) data as of July 2026: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide. The FDA 503B comment period on the exclusion closed Thursday July 30, 2026.
Six weeks ahead of the FDA's June 29 closing date for public comments on the April 30 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide, the compounded-GLP-1 telehealth segment has settled into a defensive pricing structure. Ozari Health's May 19 launch at $86/month compounded semaglutide and $120/month compounded tirzepatide established the floor; comparable platforms have held prices steady at $99-249/month rather than competing further on price. The Saturday market sentiment is split: bull case is that the FDA's final determination could grandfather existing 503A patients under a transition window, leaving cash-pay compounded GLP-1 viable through 2027; bear case is that the BSR Intelligence-documented 90% YoY drop in compounded semaglutide shipments accelerates as 503B compounding ends, with only the smallest-volume 503A pharmacies remaining. Patient migration toward branded Wegovy via Novo's Hims & Hers branded-distribution channel (125K shipments in six weeks) is the natural off-ramp.
The FDA sent a warning letter to Harbin Jixianglong Biotech disclosed May 20 after inspectors discovered a compliance failure at the company's manufacturing facility two months after the firm had been added to the FDA's green list to export GLP-1 drugs to the US. Jixianglong allegedly bought semaglutide active pharmaceutical ingredient from a facility not on the green list, labeled the API as manufactured at its own plant (implying the green-listed origin), and shipped the batch to US customers. The FDA framed the labeling as an apparent attempt to circumvent import-alert safeguards. The agency's March 11 enforcement report had previously listed Jixianglong recalls of semaglutide for compounding use only, attributed to failing to complete process validation and bacterial endotoxin method validation before distribution. The action is part of the broader FDA Pharmaceutical Quality / GLP-1 supply-chain enforcement cycle, including the April 30 503B bulks-list proposal closing June 29.
Ozari Health, a New York-based telehealth company, launched a nationwide platform on Tuesday May 19, 2026 offering compounded semaglutide starting at $86/month and compounded tirzepatide starting at $120/month, with branded options (Wegovy, Ozempic, Mounjaro, Zepbound) available through the same channel. Patients complete an online intake, get evaluated by state-licensed providers, and receive prescriptions filled by partner compounding pharmacies including Hallandale Pharmacy and VialsRX — the multi-pharmacy partner structure differentiates Ozari from telehealth platforms that work with a single compounding partner. Ozari pricing sits at the floor of the compounded GLP-1 market; comparable platforms (Sesame, Henry Meds, Wisp) range $99-249/month for compounded semaglutide. The launch lands as the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (comments closing June 29) puts long-term compounding-pharmacy access in question.
UK-based BSR — Biotech Scientific Research — published a peptide industry briefing covering March through early-May 2026 with concrete supply-chain and quality-control data points. Compounded semaglutide shipment volumes are down 90% year-over-year and tirzepatide down 34% as the FDA-declared shortage resolution shifts demand back to branded supply; the April 30 proposal to exclude both drugs from the 503B bulks list continues to compress the compounded segment with comments closing June 29. On the quality side, the briefing cites the 2018 falsification analysis showing research-peptide purity ranging from 5% to 75% with lead concentrations 10x safety limits, plus current evidence of fake Certificates of Analysis from Chinese-sourced products that don't match actual contents. The 'CORE PEPTIDES' scam was flagged January 2026 with documented $500 losses via Cash App and no recourse. 455+ FDA adverse-event reports for compounded semaglutide alone trace back to dosing errors from patients self-administering incorrect doses from multidose vials.
Tuesday's Ozari Health launch at $86/month for compounded semaglutide and $120/month for compounded tirzepatide places the platform at the low end of the compounded GLP-1 telehealth pricing band. Comparable platforms in the same market: Sesame ~$99/month, Henry Meds $129-249/month, Wisp ~$199/month, Mochi Health $129/month introductory, MD Lifestyle $99-249/month. The pricing-floor compression is colliding with the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — comments close June 29, with the final determination expected late Q3 2026. If the FDA's 503B proposal stands, large-scale 503B compounding ends and platforms either shift to 503A pharmacies (lower volume, higher unit cost) or wind down. The current cohort of telehealth launches at $86-129/month likely represents the cheapest US compounded GLP-1 will be before the regulatory regime tightens. Branded Wegovy and Foundayo's $25-149/month commercial-insurance copays remain the lower-cost path for insured patients; the cash-pay compounded market is what these telehealth launches are competing for.
A University of Colorado Anschutz-led secret shopper study presented at Obesity Medicine Association 2026 surveyed 75 weight-loss clinics and medspas across two US states. 69 of 74 still offered compounded semaglutide and 65 of 74 offered compounded tirzepatide despite FDA resolving the name-brand shortages. Four source facilities had received FDA warnings or state licensing discipline since 2023 — three related to sterile compounding. Many clinics report using 'additive' formulations to skirt compounding restrictions.